KR101572703B1 - 물에 난용성인 제약학적 활성 물질의 투여를 위한 약물 전달 시스템 - Google Patents

물에 난용성인 제약학적 활성 물질의 투여를 위한 약물 전달 시스템 Download PDF

Info

Publication number
KR101572703B1
KR101572703B1 KR1020107015610A KR20107015610A KR101572703B1 KR 101572703 B1 KR101572703 B1 KR 101572703B1 KR 1020107015610 A KR1020107015610 A KR 1020107015610A KR 20107015610 A KR20107015610 A KR 20107015610A KR 101572703 B1 KR101572703 B1 KR 101572703B1
Authority
KR
South Korea
Prior art keywords
sodium salt
retinoyl
acid methyl
methyl ester
cysteine acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020107015610A
Other languages
English (en)
Korean (ko)
Other versions
KR20100094575A (ko
Inventor
줄리안 알렉소브
아이고르 로코트
Original Assignee
아데니아 인베스트먼츠, 엘티디.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40795732&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR101572703(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 아데니아 인베스트먼츠, 엘티디. filed Critical 아데니아 인베스트먼츠, 엘티디.
Publication of KR20100094575A publication Critical patent/KR20100094575A/ko
Application granted granted Critical
Publication of KR101572703B1 publication Critical patent/KR101572703B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Transplantation (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020107015610A 2007-12-19 2008-12-18 물에 난용성인 제약학적 활성 물질의 투여를 위한 약물 전달 시스템 Active KR101572703B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SEPCT/SE2007/001127 2007-12-19
PCT/SE2007/001127 WO2009078754A1 (en) 2007-12-19 2007-12-19 Drug delivery system for administration of poorly water soluble pharmaceutically active substances

Publications (2)

Publication Number Publication Date
KR20100094575A KR20100094575A (ko) 2010-08-26
KR101572703B1 true KR101572703B1 (ko) 2015-11-27

Family

ID=40795732

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020107015610A Active KR101572703B1 (ko) 2007-12-19 2008-12-18 물에 난용성인 제약학적 활성 물질의 투여를 위한 약물 전달 시스템

Country Status (27)

Country Link
US (4) US8999382B2 (https=)
EP (1) EP2231189B1 (https=)
JP (1) JP5466172B2 (https=)
KR (1) KR101572703B1 (https=)
CN (1) CN101951956B (https=)
AU (1) AU2008339099B2 (https=)
BR (1) BRPI0821740B1 (https=)
CA (1) CA2709266C (https=)
CY (2) CY1119805T1 (https=)
DK (1) DK2231189T3 (https=)
EA (1) EA015247B1 (https=)
ES (1) ES2650242T3 (https=)
FR (1) FR19C1030I1 (https=)
HR (1) HRP20171796T1 (https=)
HU (1) HUE034684T2 (https=)
LT (2) LT2231189T (https=)
LU (1) LUC00117I2 (https=)
MX (1) MX2010006914A (https=)
MY (2) MY157187A (https=)
NL (1) NL300987I9 (https=)
NO (2) NO2231189T3 (https=)
NZ (1) NZ586859A (https=)
PL (1) PL2231189T3 (https=)
PT (1) PT2231189T (https=)
SI (1) SI2231189T1 (https=)
WO (2) WO2009078754A1 (https=)
ZA (1) ZA201004685B (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009078756A1 (en) 2007-12-19 2009-06-25 Ardenia Investments, Ltd. Drug delivery system for administration of a water soluble, cationic and amphiphilic pharmaceutically active substance
WO2009078755A1 (en) 2007-12-19 2009-06-25 Ardenia Investments, Ltd. Drug delivery system for administration of a water soluble, cationic and amphiphilic pharmaceutically active substance
WO2009078754A1 (en) * 2007-12-19 2009-06-25 Ardenia Investments, Ltd. Drug delivery system for administration of poorly water soluble pharmaceutically active substances
KR20120022984A (ko) * 2009-04-21 2012-03-12 셀렉타 바이오사이언시즈, 인크. Ｔｈ１ 편향 반응을 제공하는 면역나노치료법
AU2011258165B2 (en) 2010-05-26 2016-11-17 Selecta Biosciences, Inc. Dose selection of adjuvanted synthetic nanocarriers
WO2012061717A1 (en) 2010-11-05 2012-05-10 Selecta Biosciences, Inc. Modified nicotinic compounds and related methods
CN103908432B (zh) * 2013-01-02 2018-09-21 博瑞生物医药（苏州）股份有限公司 一种伊沙匹隆白蛋白的冻干组合物及其制备方法
CN112321465B (zh) 2019-07-18 2023-06-06 上海现代药物制剂工程研究中心有限公司 一种含苯基化合物、其中间体、制备方法及应用
CN112239418B (zh) * 2019-07-18 2023-07-07 上海现代药物制剂工程研究中心有限公司 视黄醇类化合物及其钠盐的制备方法
WO2021259472A1 (en) * 2020-06-24 2021-12-30 Oasmia Pharmaceutical Ab Micellar docetaxel for use in the treatment of cancer
CN115429886B (zh) * 2021-06-02 2025-10-31 复旦大学 一种药物纳米结晶制剂及其制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040048923A1 (en) * 2002-07-23 2004-03-11 Oleg Strelchenok Therapeutic compounds

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6096331A (en) * 1993-02-22 2000-08-01 Vivorx Pharmaceuticals, Inc. Methods and compositions useful for administration of chemotherapeutic agents
DE19839566C2 (de) * 1998-08-31 2002-01-17 Fumapharm Ag Muri Verwendung von Fumarsäurederivaten in der Transplantationsmedizin
US6197809B1 (en) * 1998-12-23 2001-03-06 Ardenia Investments Ltd. Compounds for the treatment of cancer
US6656504B1 (en) 1999-09-09 2003-12-02 Elan Pharma International Ltd. Nanoparticulate compositions comprising amorphous cyclosporine and methods of making and using such compositions
SE0101702D0 (sv) * 2001-05-15 2001-05-15 Ardenia Investments Ltd Novel potentiating compounds
US20050249786A1 (en) * 2001-09-28 2005-11-10 Solubest Ltd. Hydrophilic dispersions of nanoparticles of inclusion complexes of amorphous compounds
US20050191359A1 (en) * 2001-09-28 2005-09-01 Solubest Ltd. Water soluble nanoparticles and method for their production
EP1534672B1 (en) * 2002-07-23 2013-05-01 Ardenia Investments Ltd. Retinol derivatives, their use in the treatment of cancer and for potentiating the efficacy of other cytotoxic agents
US7259984B2 (en) * 2002-11-26 2007-08-21 Cornell Research Foundation, Inc. Multibit metal nanocrystal memories and fabrication
JP2006199590A (ja) 2003-09-04 2006-08-03 Nano Career Kk 水溶性の塩基性薬物内包ナノ粒子含有組成物
WO2005089106A2 (en) 2004-02-27 2005-09-29 Molecular Therapeutics, Inc. Degradable nanoparticles
US7871632B2 (en) 2004-07-12 2011-01-18 Adventrx Pharmaceuticals, Inc. Compositions for delivering highly water soluble drugs
US8945629B2 (en) * 2004-09-10 2015-02-03 University Of Wyoming Nanoparticles for cytoplasmic drug delivery to cancer cells
AU2006284657B2 (en) * 2005-08-31 2012-07-19 Abraxis Bioscience, Llc Compositions and methods for preparation of poorly water soluble drugs with increased stability
WO2009078756A1 (en) 2007-12-19 2009-06-25 Ardenia Investments, Ltd. Drug delivery system for administration of a water soluble, cationic and amphiphilic pharmaceutically active substance
WO2009078755A1 (en) 2007-12-19 2009-06-25 Ardenia Investments, Ltd. Drug delivery system for administration of a water soluble, cationic and amphiphilic pharmaceutically active substance
WO2009078754A1 (en) * 2007-12-19 2009-06-25 Ardenia Investments, Ltd. Drug delivery system for administration of poorly water soluble pharmaceutically active substances

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040048923A1 (en) * 2002-07-23 2004-03-11 Oleg Strelchenok Therapeutic compounds

Also Published As

Publication number Publication date
CN101951956A (zh) 2011-01-19
NL300987I9 (nl) 2019-05-16
AU2008339099B2 (en) 2015-08-13
HRP20171796T1 (hr) 2018-01-26
BRPI0821740B1 (pt) 2021-05-18
CY1119805T1 (el) 2018-06-27
NO2231189T3 (https=) 2018-02-03
ZA201004685B (en) 2011-03-30
CN101951956B (zh) 2012-10-17
EA200802350A3 (ru) 2009-10-30
NL300987I2 (https=) 2019-05-09
LUC00117I2 (https=) 2024-05-22
EA200802350A2 (ru) 2009-06-30
CY2019021I2 (el) 2019-11-27
AU2008339099A1 (en) 2009-06-25
LTPA2019508I1 (lt) 2019-05-10
KR20100094575A (ko) 2010-08-26
EP2231189A4 (en) 2013-10-09
PL2231189T3 (pl) 2018-03-30
MY157187A (en) 2016-05-13
MX2010006914A (es) 2010-11-10
ES2650242T3 (es) 2018-01-17
EA015247B1 (ru) 2011-06-30
JP5466172B2 (ja) 2014-04-09
US20110014281A1 (en) 2011-01-20
DK2231189T3 (en) 2017-12-11
NZ586859A (en) 2012-06-29
BRPI0821740A2 (pt) 2020-02-27
USRE49741E1 (en) 2023-12-05
USRE49742E1 (en) 2023-12-05
US9993438B2 (en) 2018-06-12
JP2011507838A (ja) 2011-03-10
EP2231189B1 (en) 2017-09-06
MY157186A (en) 2016-05-13
CA2709266C (en) 2017-09-26
CY2019021I1 (el) 2019-11-27
NO2019023I1 (no) 2019-05-08
US20150164819A1 (en) 2015-06-18
US8999382B2 (en) 2015-04-07
FR19C1030I1 (fr) 2019-06-21
EP2231189A1 (en) 2010-09-29
LT2231189T (lt) 2017-12-27
HUE034684T2 (en) 2018-02-28
WO2009078754A1 (en) 2009-06-25
SI2231189T1 (en) 2018-03-30
WO2009078802A1 (en) 2009-06-25
CA2709266A1 (en) 2009-06-25
PT2231189T (pt) 2017-12-12

Similar Documents

Publication Publication Date Title
KR101572703B1 (ko) 물에 난용성인 제약학적 활성 물질의 투여를 위한 약물 전달 시스템
RU2451510C2 (ru) Композиции и способы получения слаборастворимых в воде лекарственных средств с увеличенной стабильностью
US20190015335A1 (en) Hepatoprotective particles and systems and methods of use thereof
EP3138555B1 (en) Liposome composition and production method therefor
CN105287383A (zh) 新型米托蒽醌脂质体联合化疗药物在抗肿瘤治疗中的应用
JP5466173B2 (ja) 水溶性、カチオン性および両親媒性の薬学的に活性な物質を投与するためのドラッグ・デリバリー・システム
KR101616135B1 (ko) 수용성의 양이온성 양친매성 제약학적 활성 물질의 투여를 위한 약물 전달 시스템
CN101209251A (zh) 含有紫杉醇或多烯紫杉醇的弹性纳米囊泡制剂及其制备方法
CN112741828B (zh) 药物联用物及其制备方法和用途
UA96273C2 (uk) Композиція доцетакселу і цитрату для лікування раку

Legal Events

Date Code Title Description
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R11-asn-PN2301

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R11-asn-PN2301

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 9

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 10

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 11

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 11